Roxastat is a new hypoxia inducible factor (HIF) - prolyl hydroxylase (PH) enzyme inhibitor. It can stabilize HIF, inhibit its degradation, activate the transcription of related genes, produce corresponding physiological responses, moderately increase the concentration of erythropoietin and improve erythropoietin (EPO) receptor sensitivity, coordinate the production of erythrocytes, reduce the level of ferritin, increase the content and activity of transferrin receptor, promote the absorption and utilization of iron, and it is well tolerated.